Tag: AVF

Vascular Therapies announces clinical results from phase 3 randomised multicentre clinical...

Vascular Therapies recently announced results from its phase 3 clinical trial in which Sirogen showed encouraging arteriovenous fistula (AVF) outcomes in elderly end-stage renal...
Artio Medical

Artio Medical announces successful first human use of the Amplifi vein...

Artio Medical recently announced that it has successfully completed the first human use of its Amplifi vein dilation system. The first clinical procedure was...
patency

Arterial diameter may help to predict AVF aneurysm progression, study suggests

A recent study concludes that arterial diameter may influence arteriovenous fistula (AVF) aneurysm progression and the interval to surgical revision. “Patients with larger arterial...
VasQ

VasQ device improves AVF creation in haemodialysis patients

VasQ, a high haemocompatibility biosynthetic vascular device from Laminate Medical Technologies, could be protective against the haemodynamic modifications that occur during arteriovenous fistulae (AVF)...
natural

Alucent Biomedical adds to scientific advisory board, expands portfolio with AF...

Alucent Biomedical has announced Stanford vascular surgeon Venita Chandra (Stanford University Medical Center, Stanford, USA) will join the company’s scientific advisory board. The news...

Patient-specific computation model may improve AVF maturation rates

The results of a randomised controlled trial—the Shunt simulation study—show that a new patient-specific computation model accurately calculated postoperative access flow. As flow is...
Artio Medical

Artio Medical acquires Flow Forward Medical, expanding their peripheral vascular portfolio

Artio Medical today announced it has acquired Flow Forward Medical, a medical device company developing methods for establishing and maintaining vascular access sites. This...

APERTO becomes the first drug-coated balloon to be approved in China...

APERTO, Cardionovum’s paclitaxel-coated balloon for arterio-venous access, has received market approval for China, making it the first high pressure drug-coated balloon (DCB) available in...

VIVA 2019: IN.PACT AV DCB shows “consistent effectiveness performance” in subgroup...

Today Medtronic shared a six-month subgroup analysis from the IN.PACT AV Access trial, which evaluated how the IN.PACT AV DCB—an investigational device not currently...

Comparing and contrasting surgically-created AVFs with those made by endovascular means

 Nicholas Inston (Birmingham, UK) tells Vascular News at LINC 2019 about the exciting field of percutaneous arteriovenous fistula (AVF) creation, the main devices and...

Flow Forward Medical exceeds US$8 million investments, awarded grant from NIH

Flow Forward Medical, a medical device company focused on improving outcomes for haemodialysis patients through the rapid creation of high-quality vascular access sites, has...

Meta-analysis shows positive experience for patients who received an endovascular arteriovenous...

An international meta-analysis of clinical experience in patients who received an endovascular arteriovenous fistula (endoAVF) for haemodialysis access was presented at Leipzig Interventional Course...

TVA Medical receives CE mark for everlinQ 4 endovascular AVF system

TVA Medical’s everlinQ 4 endovascular arteriovenous fistula (AVF) system has received CE mark in the European Union. The technology uses a 4F catheter system...

Twelve-month NEAT trial data promising for everlinQ endoAVF haemodialysis access system

TVA Medical has announced the online publication of positive results from the Novel Endovascular Access Trial (NEAT) evaluating its everlinQ endoAVF system. The 12-month...
SAVE-US trial

Bluegrass Vascular announces strategic relationship with Merit Medical

Bluegrass Vascular Technologies is entering into a strategic relationship with Merit Medical Systems. The agreement will streamline European distribution of the recently CE mark-approved Surfacer Inside-Out...

Promising early results for Lutonix US IDE trial in obstructed AV...

The first US randomised controlled trial for drug-coated balloon use for arteriovenous fistula obstructions for 50 years, the Lutonix (Bard) IDE trial was a...
VasQ

VasQ series at Berlin’s Charité University Hospital produces “exceptionally promising results”

As part of the main scientific programme at Dreiländertagung 2016 (4–8 October, Bern Switzerland), Peter Olschewski has reported “exceptionally promising results” from the first...